| 08.09.2022 20:43 | DUKE, STX | EARNINGS SUMMARY: Open Orphan name change; Secured Income winds down | Alliance |
| 08.09.2022 07:00 | STX | Half-year Report | RNS |
| 01.09.2022 15:59 | VTY, SLP, SPI | UK earnings, trading statements calendar - next 7 days | Alliance |
| 01.09.2022 14:20 | JUP, STX | Holding(s) in Company | RNS |
| 01.09.2022 07:00 | STX | Launch of new corporate brand and website | Reach |
| 31.08.2022 14:00 | STX | Total Voting Rights Update | RNS |
| 31.08.2022 11:00 | STX | Notice of Interim Results | RNS |
| 30.08.2022 09:30 | STX | Holding(s) in Company | RNS |
| 12.08.2022 11:45 | STX | Hardman & Co: Q&A on Shield Therapeutics (STX): Upside potential is enormous | EQS |
| 09.08.2022 16:45 | STX | Grant of share options | RNS |
| 01.08.2022 19:38 | STX | IN BRIEF: Shield Therapeutics to gain USD10 million loan from AOP | Alliance |
| 01.08.2022 07:00 | STX | Completion of Loan Agreement & Partial Conversion | RNS |
| 27.07.2022 16:20 | STX | Results of 2022 General Meeting | RNS |
| 27.07.2022 16:15 | STX | Results of 2022 Annual General Meeting | RNS |
| 26.07.2022 07:15 | STX | Hardman & Co Research: Shield Therapeutics (STX): Looking to accelerate positive signals in the US | EQS |
| 20.07.2022 16:03 | TAM, STX, MOTR | UK shareholder meetings calendar - next 7 days | Alliance |
| 14.07.2022 21:44 | STX, GGP, CAPD | TRADING UPDATES: Shield closer to Canada approval; Angle plans raise | Alliance |
| 14.07.2022 07:00 | STX | New Drug Submission accepted by Health Canada | RNS |
| 08.07.2022 07:00 | STX | Notice of General Meeting | RNS |
| 30.06.2022 16:41 | STX | Second Price Monitoring Extn | RNS |
| 30.06.2022 16:36 | STX | Price Monitoring Extension | RNS |
| 30.06.2022 14:06 | STX | Second Price Monitoring Extn | RNS |
| 30.06.2022 14:00 | STX | Price Monitoring Extension | RNS |
| 30.06.2022 13:53 | ANGS, TAN, OBOR | EARNINGS UPDATES: Kingswood revenue surges; Shield in loan deal | Alliance |
| 30.06.2022 11:05 | STX | Second Price Monitoring Extn | RNS |
| 30.06.2022 11:00 | STX | Price Monitoring Extension | RNS |
| 30.06.2022 09:05 | STX | Second Price Monitoring Extn | RNS |
| 30.06.2022 09:00 | STX | Price Monitoring Extension | RNS |
| 30.06.2022 07:01 | STX | 2021 Annual Report and 2022 AGM Notice | RNS |
| 30.06.2022 07:00 | STX | Business Update, Final Results&Financing Agreement | RNS |
| 29.06.2022 07:00 | STX | Notice of Results | RNS |
| 28.06.2022 16:40 | STX | Second Price Monitoring Extn | RNS |
| 28.06.2022 16:35 | STX | Price Monitoring Extension | RNS |
| 28.06.2022 14:05 | STX | Second Price Monitoring Extn | RNS |
| 28.06.2022 14:00 | STX | Price Monitoring Extension | RNS |
| 29.04.2022 07:00 | STX | Total Voting Rights Update | RNS |
| 31.03.2022 15:50 | STX | Block Listing Application | RNS |
| 31.03.2022 15:50 | STX | Block Listing 6 Monthly Return | RNS |
| 21.03.2022 14:38 | ROCK, BRES, INHC | TRADING UPDATES: Further progress at Blencowe and Rockfire mines | Alliance |
| 21.03.2022 07:00 | STX | KYE Pharmaceuticals Files Accrufer® NDS in Canada | RNS |
| 02.03.2022 13:30 | STX | Hardman & Co Research: Shield Therapeutics (STX) - PBMs have bought in to Accrufer | EQS |
| 25.02.2022 07:00 | STX | Investor Presentation | Reach |
| 23.02.2022 14:06 | STX | Second Price Monitoring Extn | RNS |
| 23.02.2022 14:01 | STX | Price Monitoring Extension | RNS |
| 23.02.2022 11:05 | STX | Second Price Monitoring Extn | RNS |
| 23.02.2022 11:00 | STX | Price Monitoring Extension | RNS |
| 18.02.2022 14:06 | STX | Second Price Monitoring Extn | RNS |
| 18.02.2022 14:00 | STX | Price Monitoring Extension | RNS |
| 17.02.2022 11:54 | STX | Shield Therapeutics shares fall as guides for sharp 2021 revenue drop | Alliance |
| 17.02.2022 09:05 | STX | Second Price Monitoring Extn | RNS |
| 17.02.2022 09:00 | STX | Price Monitoring Extension | RNS |
| 17.02.2022 07:00 | STX | Full Year Trading Update | RNS |
| 04.02.2022 07:00 | STX | KOL Investor Event on Iron Deficiency | Reach |
| 07.01.2022 07:00 | STX | Investor Presentation | Reach |
| 05.01.2022 07:00 | STX | Licence Agreement in Canada for Accrufer® | RNS |
| 30.12.2021 09:06 | STX | Second Price Monitoring Extn | RNS |
| 30.12.2021 09:00 | STX | Price Monitoring Extension | RNS |
| 29.12.2021 11:05 | STX | Second Price Monitoring Extn | RNS |
| 29.12.2021 11:00 | STX | Price Monitoring Extension | RNS |
| 16.12.2021 11:05 | STX | Second Price Monitoring Extn | RNS |
| 16.12.2021 11:00 | STX | Price Monitoring Extension | RNS |
| 16.12.2021 07:00 | STX | Patient Access Expands for Accrufer® | RNS |
| 07.10.2021 09:45 | STX | Hardman & Co Research: Shield Therapeutics (STX) Life Sciences Investor Forum research | EQS |
| 30.09.2021 17:30 | STX | Block Listing 6 Monthly Return | RNS |
| 27.09.2021 07:00 | STX | Jose A. Menoyo Appointed as Chief Medical Officer | RNS |
| 21.09.2021 07:00 | STX | Investor presentation | Reach |
| 23.08.2021 07:00 | STX | PDMR Transaction Notification | RNS |
| 20.08.2021 11:08 | STX | Hardman & Co Research: Shield Therapeutics (STX) - Focused on US market penetration | EQS |
| 17.08.2021 07:00 | STX | Half-year Report | RNS |
| 12.08.2021 07:25 | STX | Hardman & Co Video Event | Shield Therapeutics plc - Investor Forum | EQS |
| 12.08.2021 07:00 | STX | Licence agreement secured in Republic of Korea | RNS |
| 11.08.2021 07:00 | STX | Notice of Results | RNS |
| 09.08.2021 07:00 | STX | AEGIS-CKD study results published in AJKD | Reach |
| 04.08.2021 16:41 | STX | Second Price Monitoring Extn | RNS |
| 04.08.2021 16:35 | STX | Price Monitoring Extension | RNS |
